Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Genome-wide association studies have identified over five hundred loci that contribute to variation in type 2 diabetes (T2D), an established risk factor for many diseases. However, the mechanisms and extent through which these loci contribute to subsequent outcomes remain elusive. We hypothesized that combinations of T2D-associated variants acting on tissue-specific regulatory elements might account for greater risk for tissue-specific outcomes, leading to diversity in T2D disease progression. We searched for T2D-associated variants acting on regulatory elements and expression quantitative trait loci (eQTLs) in nine tissues. We used T2D tissue-grouped variant sets as genetic instruments to conduct 2-Sample Mendelian Randomization (MR) in ten related outcomes whose risk is increased by T2D using the FinnGen cohort. We performed PheWAS analysis to investigate whether the T2D tissue-grouped variant sets had specific predicted disease signatures. We identified an average of 176 variants acting in nine tissues implicated in T2D, and an average of 30 variants acting on regulatory elements that are unique to the nine tissues of interest. In 2-Sample MR analyses, all subsets of regulatory variants acting in different tissues were associated with increased risk of the ten secondary outcomes studied on similar levels. No tissue-grouped variant set was associated with an outcome significantly more than other tissue-grouped variant sets. We did not identify different disease progression profiles based on tissue-specific regulatory and transcriptome information. Bigger sample sizes and other layers of regulatory information in critical tissues may help identify subsets of T2D variants that are implicated in certain secondary outcomes, uncovering system-specific disease progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981672PMC
http://dx.doi.org/10.1038/s41598-023-30369-6DOI Listing

Publication Analysis

Top Keywords

variants acting
20
tissue-grouped variant
16
secondary outcomes
12
regulatory elements
12
disease progression
12
variant sets
12
regulatory variants
8
type diabetes
8
loci contribute
8
t2d-associated variants
8

Similar Publications

Physical and functional effects of substituting coevolved residues from Ω-loop C of yeast Iso-1-cytochrome c into human cytochrome c.

J Inorg Biochem

September 2025

Department of Chemistry & Biochemistry, University of Montana, Missoula, MT 59812, United States; Center for Biomolecular Structure & Dynamics, University of Montana, Missoula, MT 59812, United States. Electronic address:

Omega loop C (residues 40-57) of cytochrome c (Cytc) is a common location for naturally-occurring variants of human Cytc that cause thrombocytopenia 4 (THC4). These variants are characterized by significant increases in the intrinsic peroxidase activity of Cytc, which appears to be linked to increased dynamics in Ω-loop D (residues 71-85). The mutations in Ω-loop C enhance the dynamics of Ω-loop D by decreasing the acid dissociation constant of the trigger group (pK) of the alkaline conformational transition.

View Article and Find Full Text PDF

Splicing factor Nova regulates the splice variants in exons 3 and 6 of GABA receptor subunit RDL from Chilo suppressalis Walker (Lepidoptera: Crambidae).

Pestic Biochem Physiol

November 2025

State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing 211800, PR China. Electronic address:

The insect ionotropic γ-aminobutyric acid (GABA) receptor is an important insecticide target, and alternative splicing (AS) among exons 3a, 3b, 6a, and 6b of its RDL subunit is ubiquitous in insects; however, the AS factors and mechanisms remain unclear. While the neuro-oncological ventral antigen (Nova) is known to regulate AS of the γ2 subunit of mammalian GABA receptors, its role in insects remains unexplored. Two CsNova isoforms, CsNova-X1 and CsNova-X3, were identified by BLAST in the third-generation transcriptome of Chilo suppressalis.

View Article and Find Full Text PDF

NK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2.

Int J Biol Macromol

September 2025

Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Institute of Cell The

Despite its potential as a cancer immunotherapy, wild-type IL-2 is limited by dose-limiting toxicities, including vascular leak syndrome, and its strong activation of regulatory T cells (Tregs), which dampens anti-tumor immunity. These drawbacks are largely driven by IL-2's binding to IL-2Rα, and avoiding this interaction can reduce IL-2-associated toxicities, although it cannot completely eliminate them. To overcome these limitations, βγ-biased IL-2 variants (Non-α-IL-2) have been developed to selectively activate effector T and NK cells.

View Article and Find Full Text PDF

The facultative-parasitic nematode has been used for many years as a biological control agent targeting slug pests. During the nematode's infection process, the presence of certain bacteria has been suggested to affect the pathogenicity and efficiency of the nematodes in killing slugs, though the potential roles of different bacteria in affecting host-infection by nematodes remain unclear. In this study, we examined three experimental populations cultured with three different bacteria: 1) (EC), 2) a newly isolated sp.

View Article and Find Full Text PDF

Oral pre-exposure prophylaxis (PrEP) denotes an effective strategy to reduce the risk of HIV infection. However, many individuals encounter difficulties adhering to the once-daily regimen, which highlights the need for a broader portfolio of PrEP options. The novel HIV capsid inhibitor lenacapavir (LEN), when injected every six month, has shown potential in the recently completed clinical trials.

View Article and Find Full Text PDF